Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025

Reuters

2025/11/15

<a href="https://laohu8.com/S/EMMA">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025

Emmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583568194"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583568194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583568194?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 04:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583568194","market":"us","top_or_hot":-1,"title":"Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 04:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9DzLXz:1","article_id":"2583568194","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583568194","pubTimestamp":1763153891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EMMA":"Emmaus生命科学"},"translate_title":"Emmaus Life Sciences报告2025年第三季度净收入下降38%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMMA":0.9},"content_text":"Emmaus Life Sciences Reports 38% Decline in Net Revenues for Q3 2025\n    \n\nEmmaus Life Sciences Inc. reported net revenues of $3.4 million for the three months ended September 30, 2025, a 38% decrease compared to $5.5 million in the same period in 2024. The decline was attributed to competition from generic L-Glutamine in the U.S. and lower sales in the Middle East North Africa region. Operating expenses were reduced to $2.4 million from $4.3 million, reflecting cost-cutting measures implemented in the second half of 2024. The company recorded income from operations of $0.7 million, slightly down from $0.8 million in the prior year period. Net loss for the quarter was $2.1 million, or $0.03 per share, compared to net income of $1.8 million, or $0.03 per share, in the same quarter last year. Cash and cash equivalents stood at $0.3 million as of September 30, 2025, compared to $1.4 million at the end of 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25075) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}